Beta Bionics (NASDAQ:BBNX) Shares Gap Up on Analyst Upgrade

Beta Bionics, Inc. (NASDAQ:BBNX)’s share price gapped up before the market opened on Monday after UBS Group upgraded the stock to a strong-buy rating. The stock had previously closed at $13.08, but opened at $13.69. Beta Bionics shares last traded at $13.25, with a volume of 272,867 shares.

BBNX has been the topic of several other research reports. Piper Sandler reiterated an “overweight” rating and issued a $32.00 price target (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Robert W. Baird set a $28.00 price objective on shares of Beta Bionics in a report on Tuesday, December 16th. TD Cowen began coverage on shares of Beta Bionics in a report on Monday, January 26th. They set a “hold” rating and a $17.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $26.42.

Insider Transactions at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mike Mensinger sold 7,800 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the transaction, the insider directly owned 82,952 shares of the company’s stock, valued at $2,456,208.72. The trade was a 8.59% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 32,490 shares of company stock valued at $960,835.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BBNX. GPS Wealth Strategies Group LLC raised its position in Beta Bionics by 45.0% during the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. Strs Ohio purchased a new stake in shares of Beta Bionics during the first quarter worth about $29,000. EverSource Wealth Advisors LLC raised its position in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the last quarter. CWM LLC purchased a new position in Beta Bionics in the 2nd quarter valued at about $58,000. Finally, Legal & General Group Plc lifted its stake in Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after buying an additional 2,639 shares in the last quarter.

Beta Bionics Trading Down 4.5%

The company has a fifty day moving average of $23.32 and a 200-day moving average of $22.60. The company has a market capitalization of $621.70 million and a price-to-earnings ratio of -3.23.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.